A US technology group tables a binding offer for an Israeli cyber-security company. The deal looks clean on paper. The target's IP is registered, the financial statements are audited, and the founders have signed term sheets. Six months later, the transaction has stalled at a regulatory checkpoint no one mapped in advance. This scenario repeats itself with significant frequency across cross-border M&A deals involving Israeli companies. Missed approvals, undisclosed government funding arrangements, and overlooked competition thresholds collectively cost acquirers time, money, and – in some cases – the deal itself.
Cross-border mergers involving Israel require sequential approval from Israeli corporate law authorities, and in many cases from the Israel Competition Authority and sector regulators, before closing conditions are satisfied. The share purchase agreement or statutory merger plan must reflect Israeli corporate legislation requirements, including board resolutions, shareholder votes, and – where applicable – court approval. A well-structured transaction in Israel can move from signed SPA to closing in three to four months, though complex deals with multiple regulatory touchpoints routinely take six to twelve months.
This guide walks through the procedural requirements step by step, identifies the documentary checklist. Flags the errors that consistently affect foreign acquirers. Additionally, sets out a decision framework for choosing the right deal structure in Israel.
The Israeli regulatory environment for cross-border M&A
Israeli corporate legislation – primarily the Companies Law – governs the internal mechanics of mergers involving Israeli entities. This body of law provides for two principal merger routes: the statutory merger and the share acquisition. Each triggers distinct procedural obligations.
A statutory merger requires both boards to adopt a merger plan. Shareholders of both companies must then approve it. The plan is filed with the Israel Registrar of Companies. A mandatory waiting period – typically between 50 and 70 days – follows before the merger becomes effective. During that window, creditors may object.
A share acquisition – structured through a share purchase agreement (SPA) – bypasses the merger plan procedure but does not eliminate regulatory review. If the acquisition results in a change of control in a regulated sector, the relevant sector regulator must approve the transfer before closing.
The Israel Competition Authority (ICA) – formerly the Antitrust Authority – applies merger control rules under competition legislation. A transaction must be notified to the ICA when the parties' combined Israeli turnover or market share exceeds prescribed thresholds. Filing is mandatory before closing. The ICA's review period runs up to 30 days in the first phase, with the possibility of an extended second-phase investigation lasting several months. Closing before ICA clearance is prohibited and carries material penalties.
Foreign investment review adds a further layer. Israel does not operate a single-window foreign investment screening regime equivalent to CFIUS in the United States. However, investments affecting companies operating in defence, critical infrastructure, or sensitive technology sectors may trigger review by the Ministry of Economy or specific security bodies. Foreign acquirers often underestimate this dimension when the target holds dual-use technology or contracts with Israeli defence entities.
Sector-specific regimes operate in parallel. Banking and financial services transactions require approval from the Bank of Israel. Telecommunications acquisitions require a licence transfer from the Ministry of Communications. Healthcare and pharmaceutical deals may engage the Ministry of Health. Each sector body applies its own timeline and eligibility criteria, and none is bound by the timetable of the corporate law process.
Step-by-step timeline from term sheet to closing
Understanding the sequence of steps – and their dependencies – is the foundation of realistic deal planning. The following progression applies to a typical cross-border acquisition of an Israeli private company. Statutory mergers follow a broadly similar path but with additional court and creditor notice requirements.
Step 1 – Due diligence (weeks 1–6). Thorough due diligence in Israel covers corporate records held at the Registrar of Companies. IP ownership and any Israeli Innovation Authority grant agreements, employment contracts and option plans, regulatory licences, and pending litigation. The Innovation Authority dimension is critical. Many Israeli technology targets received research and development funding under programmes administered by the Authority. Those grants create restrictions on transferring funded intellectual property outside Israel without prior approval. Discovering this obligation after signing – rather than during due diligence – forces renegotiation of closing conditions and delays the transaction.
Step 2 – Signing the SPA and related documents (weeks 6–8). The share purchase agreement sets out the representations and warranties, closing conditions, and any regulatory approval conditions precedent. Representations and warranties in Israeli cross-border deals typically follow international standards, covering title, capitalisation, IP ownership, tax compliance, and material contracts. Israeli law does not impose mandatory warranty content – parties negotiate scope freely. However, Israeli courts have held that misrepresentations can engage both contractual remedies and statutory liability under consumer and commercial legislation. The SPA should expressly state which regulatory approvals constitute conditions precedent to closing.
Step 3 – Regulatory filings (weeks 8–16 or longer). Immediately after signing, counsel files with every required authority in parallel where possible. ICA merger notification, Innovation Authority approval requests, and sector regulator licence transfer applications each have their own forms and information requirements. The ICA review period begins on the date of a complete filing. Incomplete submissions restart the clock. Foreign acquirers frequently submit incomplete ICA filings because they omit required data on the acquirer's global group turnover or market positions outside Israel.
Step 4 – Shareholder approval (weeks 10–14, for statutory mergers). Where the transaction is structured as a statutory merger, shareholder meetings must be convened with notice periods prescribed under corporate legislation. For a private company, the shareholders' agreement may modify some notice requirements, but the statutory minimum cannot be waived.
Step 5 – Satisfaction of closing conditions (weeks 14–24 or longer). All regulatory approvals must be in hand before the parties proceed to closing. A deal with three parallel approval processes – ICA, Innovation Authority, and a sector regulator – can face a bottleneck if any one authority extends its review. Parties should build long-stop dates with adequate buffer. A long-stop of six months is common; deals with security-adjacent technology or significant market position may require nine to twelve months.
Step 6 – Closing mechanics. Closing typically occurs on a single day. The buyer delivers the purchase price, the seller delivers share transfer deeds and board resignation letters, and the parties file the required post-closing notifications with the Registrar of Companies. Employment law obligations – including notification to relevant employee representatives – must be addressed at or before closing under Israeli labour legislation.
For a comparative perspective on deal structuring across other high-growth markets, our analysis of cross-border mergers in the UAE sets out the parallel approval regime in that jurisdiction.
Documentary checklist and common errors by foreign acquirers
Cross-border deals in Israel generate a substantial documentation burden. The following categories reflect the core requirements for an acquisition of an Israeli private company. Statutory mergers require additional filings with the Registrar and, in some cases, court applications.
- Corporate authorisations: board resolutions from both the Israeli target and the foreign acquirer, confirming approval of the transaction and authorising signatories.
- Merger notification package for the ICA: includes financial data for both groups, market share analysis, and a description of the transaction rationale.
- Innovation Authority notification or approval application: required where the target holds funded IP – this is a separate process from ICA review.
- Sector regulator submissions: licence transfer applications, fit-and-proper documentation for the acquirer, and evidence of financial capacity.
- Employment notifications: written notice to employee representatives and, in some cases, to the relevant works committee, as required under labour legislation.
Several errors appear with particular frequency in cross-border deals involving Israeli targets. First, foreign acquirers routinely treat Israeli due diligence as equivalent to a European or US process. It is not. The Innovation Authority grant register is a specialist search. Standard corporate due diligence checklists do not include it, and counsel unfamiliar with Israeli legislation will miss it.
Second, acquirers from common law jurisdictions sometimes resist the statutory merger route because it feels unfamiliar. The waiting period – during which creditors may object – creates perceived uncertainty. In practice, creditor objections are rare. Avoiding the statutory route in favour of a share acquisition to sidestep this concern sometimes creates greater complexity, particularly where minority shareholders hold blocking rights under Israeli corporate legislation.
Third, the representations and warranties scope is frequently under-negotiated. Israeli targets – particularly early-stage technology companies – often have complex IP chains involving university spin-out licences, open-source software components, and employee invention assignment agreements that were never formally executed. The acquirer's counsel should require specific IP warranties and a disclosure schedule that maps every material IP asset.
Fourth, closing conditions are sometimes drafted without reference to the specific Israeli approval required. A condition that reads "all required regulatory approvals" without naming the ICA, the Innovation Authority, and any applicable sector regulator creates interpretive disputes at closing.
For a fuller picture of the corporate law obligations that underpin Israeli target due diligence, our team's analysis of corporate law in Israel covers the relevant legislative regime in detail.
To receive an expert assessment of your cross-border acquisition structure in Israel, contact us at info@ferrazwhitmore.com.
Decision framework: choosing the right structure for your scenario
Not every cross-border deal involving an Israeli company follows the same path. The appropriate structure depends on the target's size, sector, shareholding profile, and IP position. The following scenarios illustrate how these variables affect the procedural route.
Scenario A – Acquisition of a private Israeli technology company with Innovation Authority-funded IP. This is the most common profile for inbound cross-border deals. The acquirer must budget for Innovation Authority approval as a standalone workstream. The approval process can take two to four months and may impose royalty obligations on future revenues derived from the funded technology. The deal timeline should not assume ICA clearance and Innovation Authority approval will run concurrently at the same pace – they frequently do not.
Scenario B – Statutory merger of an Israeli public company with a foreign acquirer. This structure is more procedurally intensive. The merger plan requires court involvement, mandatory notice to creditors, and a waiting period. Shareholders of a public Israeli company have appraisal rights under corporate legislation, meaning dissenting shareholders may seek judicial determination of fair value. Foreign acquirers must account for appraisal litigation risk when pricing the transaction and structuring their representations and warranties.
Scenario C – Acquisition of a controlling stake in an Israeli regulated entity. Where the target holds a banking licence, telecommunications licence, or healthcare authorisation, the sector regulator's approval timetable drives the deal calendar. The ICA review and the corporate law mechanics become secondary scheduling concerns. In this scenario, engaging with the relevant regulator before signing – on a pre-notification or informal basis – is strongly advisable. Regulators in Israel are generally accessible for pre-filing discussions, and early engagement materially reduces the risk of a second-phase review.
Self-assessment checklist. Before initiating a cross-border merger process in Israel, verify the following:
- Has the target received any Innovation Authority grants, and does the funded IP form part of the acquisition perimeter?
- Do the combined parties meet the ICA's merger notification thresholds in Israel?
- Does the target hold sector-specific licences that require a transfer approval from a government body?
- Does the target have contracts with Israeli government or defence entities that may trigger security review?
- Are there minority shareholders with contractual or statutory rights that could delay or block the transaction?
If the answer to any of the first four questions is yes, the deal requires parallel regulatory workstreams from the date of signing. The long-stop date should reflect the slowest of those workstreams, not the fastest.
For full-service support on M&A transactions in Israel – from due diligence through to post-closing integration – visit our M&A advisory practice for Israel.
To explore legal options for structuring your cross-border merger in Israel, schedule a consultation at info@ferrazwhitmore.com.
Frequently asked questions
Q: How long does a cross-border merger involving an Israeli company typically take?
A: The timeline depends on the complexity of the transaction and the number of regulatory approvals required. A straightforward merger with no antitrust filing and no sector-specific licence can close in three to four months. Deals requiring Israel Competition Authority review or foreign investment approval may take six to twelve months or longer, depending on remedies negotiations.
Q: Is a share purchase agreement governed by Israeli law, or can parties choose a foreign governing law?
A: Israeli contract legislation generally respects party autonomy in choosing governing law. Many cross-border share purchase agreements involving Israeli targets are governed by English or Delaware law, particularly where the acquirer is a US or European entity. However, Israeli corporate legislation governs the internal affairs of an Israeli company regardless of the SPA's governing law, and local procedural steps. such as court approval for a statutory merger – cannot be contracted around.
Q: What is the most common mistake foreign acquirers make when buying an Israeli technology company?
A: The most frequent error is failing to identify Israeli Innovation Authority grants attached to intellectual property at the due diligence stage. If the target received research and development funding from the Innovation Authority, the acquirer must obtain prior approval before transferring the funded IP outside Israel. Missing this step can block a closing or impose significant royalty obligations after the fact.
About Ferraz & Whitmore
Ferraz & Whitmore is an international law firm based in Lisbon, advising business clients across 46 jurisdictions. Our team combines Portuguese civil law expertise with English common law tradition to deliver cross-border M&A solutions, including transactions involving Israeli targets and acquirers. We have advised international entrepreneurs, institutional investors, and in-house legal teams on the full cycle of cross-border mergers in Israel – from due diligence and SPA drafting through regulatory filings and closing mechanics. As a law firm in Israel with international reach, we support clients who need results-oriented counsel navigating multi-authority approval processes across overlapping legal systems. Engaging a lawyer in Israel with cross-border M&A experience at the outset of a transaction materially reduces timeline risk. Our M&A practice covers 15 practice areas and operates across Israel, the wider Middle East, Asia-Pacific, and Europe. To discuss your cross-border merger in Israel, contact us at info@ferrazwhitmore.com.
Disclaimer: This publication is provided for informational purposes only and does not constitute legal advice. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Ferraz & Whitmore assumes no liability for actions taken or not taken based on the contents of this material. For advice regarding your particular situation, please contact info@ferrazwhitmore.com.